Aprepitant for the management of nausea with inpatient IV dihydroergotamine

Neurology

Volumn 87, Issue 15, 2016, Pages 1613-1616

  Chou, Denise E ^a,b   Tso, Amy R ^c   Goadsby, Peter J ^b,c  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CANNABIS; DIHYDROERGOTAMINE; DOMPERIDONE; GRANISETRON; ONDANSETRON; PROMETHAZINE; ANALGESIC AGENT; ANTIEMETIC AGENT; MORPHOLINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ARTICLE; CANNABIS USE; DRUG EFFICACY; DRUG MISUSE; DRUG TOLERABILITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NEW DAILY PERSISTENT HEADACHE; PREMEDICATION; PRIORITY JOURNAL; TRANSFORMED MIGRAINE; VOMITING; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE DISORDERS; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANTIEMETICS; DIHYDROERGOTAMINE; HUMANS; INPATIENTS; MIGRAINE DISORDERS; MORPHOLINES; NAUSEA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84992053128     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003206     Document Type: Article

References (10)

1. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36:995-997.
2. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine (DHE) for inpatient management of refractory primary headaches. Neurology 2011;77:1827-1832.
3. Eller M, Gelfand AA, Riggins NY, Shiboski S, Schankin C, Goadsby PJ. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Neurology 2016;86:856-859.
4. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 1999; 375:51-60.
5. Patel L, Lindley C. Aprepitant: a novel NK1-receptor antagonist. Expert Opin Pharmacother 2003;4:2279-2296.
6. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808.
7. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Proc Staff Meet Mayo Clin 1945;20:241-248.
8. Queiroz LP, Weeks RE, Rapoport AM, Sheftell FD, Baskin SM, Siegel SE. Early and transient side effects of repetitive intravenous dihydroergotamine. Headache 1996;36:291-294.
9. Coppola D, Rodriguez V, Graner K, Gunderson H. Use of aprepitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. J Pediatr Pharmacol Ther 2008;13:191.
10. Bergstrom M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004; 55:1007-1012.